Floatz logo

Pelareorep

Plasma Cell Myeloma

University of Southern Californiagene_therapyPhase 1/2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

497 Active assets in the Plasma Cell Myeloma cohort.

Asset / SponsorPhaseRating
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB
CYCLOSPORIN A
Seoul National University Hospital
Phase 3BBB
VINCRISTINE SULFATE
Roswell Park Cancer Institute
Phase 3BBB
Anti-Thymoglobulin, Rabbit
University of Birmingham
Phase 4BBB

View all 50 →

Same molecule, other indications

Pelareorep is also rated in:

breast cancerDormant
BB
Indicative ·
66 / 100
View asset →
fallopian tube carcinomaDormant
B
Indicative ·
57 / 100
View asset →
ovarian carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →